Deana Ferreri, PhD


Study Suggests Majority of Rituximab Use Is Off Label

July 02, 2020

Rituximab was originally approved in the United States in 1997 for treatment of non-Hodgkin lymphoma and has multiple additional approvals for orphan and nonorphan indications. But a recent study found off-label uses now account for more than half of patients receiving rituximab.